EC Number   |
Application |
Reference |
|---|
    1.14.14.19 | analysis |
assay based on direct electrochemistry of CYP17A1 entrapped in didodecyldimethyl ammonium bromide-modified electrode under aerobic conditions in the supporting electrolyte solution |
746506 |
| 1.14.14.19 | drug development |
CYP17 is a target for inhibitor design as a target in treatment of prostate cancer |
703551 |
| 1.14.14.19 | drug development |
the enzyme is a target for drug development in treatment of prostate cancer, in which androgens play a pivotal role, overview |
694117 |
| 1.14.14.19 | drug development |
the enzyme is a target for inhibitor design |
701962 |
| 1.14.14.19 | medicine |
CYP17 inhibitors are synthesized for the potential treatment of prostate cancer |
691232 |
| 1.14.14.19 | medicine |
inhibition of steroid 17alpha-monooxygenase is an important therapeutic strategy in order to inhibit tumor growth in prostate cancer |
390115, 390118, 390119 |
| 1.14.14.19 | medicine |
low apparent CYP17A1 activity, i.e. the combined 17alpha-hydroxylase/17,20-lyase activity, is associated with elevated daytime ambulatory blood pressure when salt intake is high. CYP17A1 activity is heritable and diminished in the elderly |
743986 |
| 1.14.14.19 | medicine |
partial 17alpha-hydroxylase/17,20-lyase deficiency is a very rare form of congenital adrenal hyperplasia |
692540 |
| 1.14.14.19 | medicine |
the vital role of CYP17 in androgen biosynthesis makes it a potential molecular target for gene therapetutic strategy |
691670 |
| 1.14.14.19 | medicine |
women with epilepsy have a higher incidence of polycystronic ovary syndrome. At concentrations normally used in antiepileptic drug therapy, the drugs valproic acid, carbamazepine, topiramate, lamotrigine do not influence 17alpha-hydroxylase/17,20-lyase and 3beta-hydroxysteroid dehydrogenase type 2 activities |
673400 |
